GB2257908B - Calcitonin analogue for transmucosal administration - Google Patents

Calcitonin analogue for transmucosal administration

Info

Publication number
GB2257908B
GB2257908B GB9214830A GB9214830A GB2257908B GB 2257908 B GB2257908 B GB 2257908B GB 9214830 A GB9214830 A GB 9214830A GB 9214830 A GB9214830 A GB 9214830A GB 2257908 B GB2257908 B GB 2257908B
Authority
GB
United Kingdom
Prior art keywords
transmucosal administration
calcitonin analogue
calcitonin
analogue
transmucosal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9214830A
Other languages
English (en)
Other versions
GB9214830D0 (en
GB2257908A (en
Inventor
Moise Azria
Gert Fricker
Jacky Vonderscher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919115202A external-priority patent/GB9115202D0/en
Priority claimed from GB929200748A external-priority patent/GB9200748D0/en
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of GB9214830D0 publication Critical patent/GB9214830D0/en
Publication of GB2257908A publication Critical patent/GB2257908A/en
Application granted granted Critical
Publication of GB2257908B publication Critical patent/GB2257908B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GB9214830A 1991-07-15 1992-07-13 Calcitonin analogue for transmucosal administration Expired - Fee Related GB2257908B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919115202A GB9115202D0 (en) 1991-07-15 1991-07-15 Improvements relating to organic compounds
GB929200748A GB9200748D0 (en) 1992-01-14 1992-01-14 Improvements relating to organic compounds

Publications (3)

Publication Number Publication Date
GB9214830D0 GB9214830D0 (en) 1992-08-26
GB2257908A GB2257908A (en) 1993-01-27
GB2257908B true GB2257908B (en) 1995-12-20

Family

ID=26299234

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9214830A Expired - Fee Related GB2257908B (en) 1991-07-15 1992-07-13 Calcitonin analogue for transmucosal administration

Country Status (7)

Country Link
JP (1) JPH05194260A (it)
BE (1) BE1007752A5 (it)
CH (1) CH685600A5 (it)
DE (1) DE4222647A1 (it)
FR (1) FR2682598B1 (it)
GB (1) GB2257908B (it)
IT (1) IT1263222B (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698521A (en) * 1995-04-04 1997-12-16 Zymogenetics, Inc. Native calcitonin mimetics
US5698672A (en) * 1995-04-04 1997-12-16 Zymogenetics, Inc. Synthetic calcitonin mimetics
WO1997021448A1 (en) * 1995-12-13 1997-06-19 Dullatur Limited A calcitonin preparation
GB9614235D0 (en) * 1996-07-06 1996-09-04 Danbiosyst Uk Composition for enhanced uptake of polar drugs from mucosal surfaces
EP0983769A4 (en) 1997-04-14 2002-05-02 Mitsubishi Tokyo Pharm Inc PERMUCOSE FORMULATION
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2127689A (en) * 1982-10-05 1984-04-18 Sandoz Ltd Calcitonin inhalation compositions
EP0122036A1 (en) * 1983-03-09 1984-10-17 Teijin Limited Powdery pharmaceutical composition for nasal administration
EP0193372A2 (en) * 1985-02-25 1986-09-03 Teijin Limited Intranasally applicable powdery pharmaceutical composition
GB2218102A (en) * 1988-04-08 1989-11-08 Sandoz Ltd Peptide derivatives
EP0432431A1 (en) * 1989-11-16 1991-06-19 PHIDEA S.p.A. Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151276A (en) * 1975-05-12 1979-04-24 Armour Pharmaceutical Company Method of suppressing gastric acid secretion by the oral administration of calcitonin
IL70489A0 (en) * 1982-12-29 1984-03-30 Armour Pharma Pharmaceutical compositions containing calcitonin
HU203204B (en) * 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
HU206367B (en) * 1988-04-30 1992-10-28 Sandoz Ag Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2127689A (en) * 1982-10-05 1984-04-18 Sandoz Ltd Calcitonin inhalation compositions
EP0122036A1 (en) * 1983-03-09 1984-10-17 Teijin Limited Powdery pharmaceutical composition for nasal administration
EP0193372A2 (en) * 1985-02-25 1986-09-03 Teijin Limited Intranasally applicable powdery pharmaceutical composition
GB2218102A (en) * 1988-04-08 1989-11-08 Sandoz Ltd Peptide derivatives
EP0432431A1 (en) * 1989-11-16 1991-06-19 PHIDEA S.p.A. Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient

Also Published As

Publication number Publication date
GB9214830D0 (en) 1992-08-26
IT1263222B (it) 1996-08-05
FR2682598A1 (fr) 1993-04-23
ITRM920535A1 (it) 1994-01-14
CH685600A5 (de) 1995-08-31
ITRM920535A0 (it) 1992-07-14
JPH05194260A (ja) 1993-08-03
GB2257908A (en) 1993-01-27
BE1007752A5 (fr) 1995-10-17
FR2682598B1 (fr) 1996-04-05
DE4222647A1 (de) 1993-01-21

Similar Documents

Publication Publication Date Title
ZA924719B (en) Pharmaceutical composition
GB9210579D0 (en) Pharmaceutical composition
GB9210974D0 (en) Pharmaceutical composition
AP9200382A0 (en) Pharmaceutical formulations
OA09535A (en) Pharmaceutical composition
GB9108080D0 (en) Pharmaceutical composition
GB9103302D0 (en) Pharmaceutical formulations
IL102435A0 (en) Pharmaceutical composition
GB2257908B (en) Calcitonin analogue for transmucosal administration
IL103226A0 (en) Pharmaceutical compositions containing calcitonin
GB2252497B (en) Pharmaceutical composition
ZA921848B (en) Pharmaceutical composition
GB9111477D0 (en) Pharmaceutical composition
GB9113380D0 (en) Dosage form
GB9111210D0 (en) Pharmaceutical composition
ZA923671B (en) Pharmaceutical composition
GB9125862D0 (en) Pharmaceutical composition
GB9123491D0 (en) Pharmaceutical composition
GB9500393D0 (en) Pharmaceutical composition
HU9401681D0 (en) Pharmaceutical composition
GB9122967D0 (en) Pharmaceutical composition
GB9121138D0 (en) Pharmaceutical composition
GB9118343D0 (en) Pharmaceutical composition
GB9117360D0 (en) Pharmaceutical composition
ZA921849B (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19970713